Dabigatran Etexilate Mesylate is an oral capsule used to prevent stroke and harmful blood clots. It is reversible direct thrombin inhibitor dabigatran. It may be used to reduce the risk of venous thromboembolic events in people undergoing anticoagulation therapy. Dabigatran Etexilate Mesylate was approved by the FDA in 2010.
Class of Drugs – Anticoagulant
Molecular Formula – C35H45N7O8S
Molecular Weight – 723.8 g/mol
Working: This medicine is a competitive, direct thrombin inhibitor because thrombin enables the conversion of fibrinogen into fibrin during the coagulation cascade. The inhibition prevents the development of a thrombus. It induced platelet aggregation that is inhibited by the active moieties. Given component is an anticoagulant that blocks a certain substance i.e. a clotting protein called thrombin in the blood. This helps to keep blood flowing smoothly in the body.
Uses: This given active ingredient Dabigatran Etexilate Mesylate is an anticoagulant used to prevent stroke and harmful blood clots in legs or lungs. It is also used to treat blood clots in the veins of the legs or lungs and to reduce the risk of them occurring again. Mentioned medication may also be used to prevent these blood clots from forming after hip replacement surgery.
This medicine should not be used to prevent blood clots from forming after artificial heart valve replacement.
Popular Brands and Dosages: This active component is used in a popular brand medicine as mentioned below:
- Pradaxa: 75 mg, 110 mg, and 150 mg
Avoid getting injections into the muscles while treating with Dabigatran Etexilate Mesylate.